Magdalena B. Wozniak
Dublin, L, Ireland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies.
Journal: International journal of dermatology
Published: June 20, 2025
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 Trials.
Journal: Dermatology and therapy
Published: January 27, 2025
The Hidradenitis Suppurativa Symptom and Impact Diary: Development and psychometric evaluation of a novel set of patient-reported outcomes for hidradenitis suppurativa.
Journal: The British journal of dermatology
Published: May 31, 2024
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: April 03, 2024
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Journal: The British journal of dermatology
Published: December 07, 2023
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 14, 2023
Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background.
Journal: American journal of human genetics
Published: March 23, 2023
Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials.
Journal: Journal of the American Academy of Dermatology
Published: February 20, 2023
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Journal: Lancet (London, England)
Published: November 29, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026